stockrow
Monday 9 November 2026
Export RMTI’s income statement to Excel — free account
Rockwell Medical, Inc.
RMTIHealthcare Drug Manufacturers Specialty & Generic
Rockwell Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $69.3 million, down 31.8% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- +32.0%
- Free cash flow
- −12.9%
- Total debt
- −1.73%
Quarter to June 2026, against a year earlier
7.73
0.13
+1.71%
Follow RMTI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.31 | 0.52 | 0.43 | 0.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
10.49 | (210.78) | 13.10 | (33.08) | |
P/B ratio |
0.62 | 0.98 | 0.81 | 1.17 | |
Price to Tangible BV |
0.88 | 1.38 | 1.14 | 1.64 | |
EV/Sales |
0.09 | 0.30 | 0.29 | 0.45 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
2.11 | 7.67 | (29.99) | (16.46) | |
EV/FCF |
(6.24) | (26.75) | (5.07) | (6.09) | |
Quick Ratio |
2.96 | 3.32 | 3.46 | 3.34 | |
Current Ratio |
3.25 | 3.74 | 3.98 | 3.92 | |
Net Debt/EBITDA |
32.77 | 16.78 | (66.95) | 15.30 | |
Debt/Assets |
16.10% | 15.85% | 15.98% | 15.93% | |
Debt/Equity |
0.26 | 0.25 | 0.25 | 0.25 | |
Asset Turnover |
1.27 | 1.22 | 1.19 | 1.32 | |
Operating CF/Net income |
(1.57) | 0.10 | (5.71) | 0.75 | |
Capex/Depreciation |
(1.06) | (0.42) | (0.14) | (0.36) | |
Interest Coverage |
(3.78) | (5.25) | (1.39) | (5.56) | |
Research and Development Expense of Revenue |
0.22% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
23.98% | 25.25% | 23.31% | 24.21% | |
Intangible Assets out of Total Assets |
0.18 | 0.18 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
2.27% | 2.76% | 2.49% | 3.34% | |
Graham Net Nets |
0.68 | 0.44 | 0.60 | 0.39 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(24.32%) | (16.80%) | (17.99%) | (13.33%) | |
Free Cash Flow Yield |
(4.49%) | (2.17%) | (12.99%) | (13.03%) | |
Revenue per Share |
4.49 | 4.40 | 5.10 | 4.42 | |
Operating CF per Share |
0.53 | (0.04) | 0.64 | (0.36) | |
Capex per Share |
(0.16) | (0.06) | (0.02) | (0.06) | |
Free Cash Flow per Share |
0.37 | (0.11) | 0.61 | (0.43) | |
Cash per Share |
6.26 | 6.06 | 6.95 | 6.58 | |
Shareholders Equity per Share |
8.86 | 9.10 | 10.28 | 10.28 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.86 | 9.10 | 10.28 | 10.28 | |
Free Cash Flow |
1.46 | (0.42) | 2.21 | (1.54) | |
Working Capital |
25.19 | 27.08 | 28.58 | 27.93 | |
Capital Expenditures |
(0.62) | (0.25) | (0.09) | (0.23) | |
Net Current Asset Value |
14.92 | 15.38 | 18.00 | 17.05 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.19 | 9.25 | 8.22 | 8.61 | |
Average Payables |
2.34 | 2.69 | 2.43 | 2.07 | |
Average Inventory |
3.49 | 4.05 | 4.60 | 4.93 | |
Average Assets |
54.58 | 55.69 | 58.18 | 57.29 | |
Average Common Equity |
32.75 | 33.69 | 34.78 | 33.08 |
Columns are period end dates · fundamentals updated 26 Oct 2026